
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific is a company with a strong market presence and a broad range of products in the cardiovascular and med-surg markets, leading to double-digit revenue growth and strong profitability. Despite a recent dip in sales for their WATCHMAN product, the company's diverse product pipeline and cost reduction efforts should support future earnings growth. With a valuation below that of their competitors and potential for upside from new products and M&A, we maintain a Buy rating for this stock.
Bears say
Boston Scientific is facing several headwinds, including a slowdown in WATCHMAN sales, workflow challenges for physicians, recent clinical trials impacting sales, and reductions in physician reimbursement for stand-alone procedures. These factors are expected to lead to flat sequential sales in 2Q and 3Q 2026, and a decline in sales in 2026. However, the company remains confident in its organic revenue growth and profitability targets. Despite these headwinds, our model forecasts a 6% organic growth in 2027 and 2028, warranting a 16.0x P/E multiple. Nevertheless, there are also risks to our rating, including FTC review, competition, acquisition hurdles, and regulatory and clinical trial risks.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares